Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

BACKGROUND: A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ly-Mee, Bafadhel, Mona, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R, Gbinigie, Oghenekome, Van Hecke, Oliver, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas P B, Patel, Mahendra G, Richards, Duncan, Berry, Nicholas, Detry, Michelle A, Saunders, Christina, Fitzgerald, Mark, Harris, Victoria, Shanyinde, Milensu, de Lusignan, Simon, Andersson, Monique I, Barnes, Peter J, Russell, Richard E K, Nicolau, Dan V, Ramakrishnan, Sanjay, Hobbs, F D Richard, Butler, Christopher C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354567/
https://www.ncbi.nlm.nih.gov/pubmed/34388395
http://dx.doi.org/10.1016/S0140-6736(21)01744-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354567/
https://www.ncbi.nlm.nih.gov/pubmed/34388395
http://dx.doi.org/10.1016/S0140-6736(21)01744-X

Ejemplares similares